Tirzepatide® providers &
prescriptions in Yuma, AZ
Verified Tirzepatide providers in Yuma, AZ. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]
Find a Tirzepatide provider in Arizona.
Every entry is checked against the NPI registry and the Arizona medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.
How to get Tirzepatide in Yuma.
29 GLP-1 prescribers and 7 local resource types are on record for Yuma, plus 3 nearby towns in the directory.
Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Arizona’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.
The molecule in Mounjaro and Zepbound. It acts on two gut-hormone pathways, GIP and GLP-1.
Tirzepatide is a once-weekly injection sold by Eli Lilly as Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management). It is the first approved dual GIP/GLP-1 receptor agonist. It activates two gut-hormone pathways rather than one, which is associated with greater average weight loss than single GLP-1 agonists.[2][3]
In SURMOUNT-1, adults with obesity (without diabetes) lost a mean of 20.9% of body weight on the 15 mg dose at 72 weeks, versus 3.1% on placebo. In the SURPASS-2 head-to-head diabetes trial, tirzepatide produced larger HbA1c and weight reductions than semaglutide 1 mg.[1]
Community health · CDC
Weight & metabolic health in Yuma
Yuma, Arizona has a population of 95,548 people. The adult obesity rate in Yuma is an age-adjusted estimate of 38.1%, 4.8 percentage points above the Arizona state rate of 33.3%. Diagnosed diabetes reaches 12.4% of adults in Yuma. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 26.1% of adults in Yuma.
- of Yuma adults have obesity
- 38.1%
- diagnosed diabetes
- 12.4%
- no regular physical activity
- 26.1%
Age-adjusted estimates for Yuma, community figures, not individual risk. CDC PLACES, 2025 release.
The prescription is one part. Here is the rest, in Yuma.
Trials of tirzepatide paired the drug with diet counseling and regular activity. Every name below is a real listing near Yuma, AZ, ordered as the registry lists them, never by who pays us.
Fitness clubs and recreation centers
Fitness clubs and recreation centers run classes and pools, an easier start than a weight room.
Registered dietitians
A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.
What the trials actually showed.
We summarize the SURMOUNT weight-management program and the SURPASS diabetes program, including the SURPASS-2 head-to-head against semaglutide. Figures are means at each trial's primary endpoint.
Most side effects are gastrointestinal and resolve within weeks.
The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]
Most directories hide the price. We don't.
Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.
Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.
NPI-verified Tirzepatide (tirzepatide) prescribers and clinics, ordered by availability, never by who pays us.
Find NPI-verified Tirzepatide (tirzepatide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.
The questions people ask before they book.
Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.
Yes. Tirzepatide is the active molecule in both Eli Lilly products. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. They are the same drug with different approved indications, and insurers treat them as separate products.[1]